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The reclassification from Propionibacterium acnes to Cutibac-
terium acnes was proposed in 2016.1 A standardized method to
perform molecular typing of C. acnes, according to the degree of
resolution needed (phylotypes, clonal complexes, single-locus
sequence typing), has been recently suggested.2
In the first article of this supplement, the authors review the
most recent data on C. acnes and its involvement in etiopatho-
genesis of acne.3 New findings on C. acnes have revealed that,
contrary to what was previously thought, its proliferation is not
the trigger of acne. A tight equilibrium between members of the
skin flora and C. acnes phylotypes might play a more critical role
in acne onset. Loss of microbial diversity can indeed lead to
chronic inflammatory skin diseases. In particular, the presence
of C. acnes phylotypes in patients with acne and healthy subjects
is discussed: some C. acnes strains and unique genomic
sequences seem to be associated with acne development and
severity. In the same article, a review of the state of the art on
virulence factors, the role and importance of biofilms in resis-
tance of C. acnes to antibiotics and the relationships between
phylotypes and antibacterial susceptibility are presented.3
The second article is on Myrtacine activity in acne.4 Myrtle
(Myrtus communis Linnaeus 1753) belongs to the family Myr-
taceae. More than 40 different varieties of myrtle are known. It
grows in arid grounds, mainly in Sardinia, but also in Spain,
Corsica, Greece, Tunisia and Algeria. The liqueur (‘mirto’)
obtained from its fruits is famous. Myrtacine is an ethanolic
extract of myrtle leaves.5 It contains 6% A and B myrtucommu-
lones (or acylphloroglucinol), with antibacterial activity, and
15%–20% ursolic acid, with anti-inflammatory activity.5 An
antiproliferative action has also been demonstrated: Myrtacine
inhibits keratinocyte proliferation by 27% and 76% at 1 and
3 lg/mL, respectively.5 At concentrations ranging from 0.0001%
to 0.03%, Myrtacine inhibits the proliferation of planktonic
and non-planktonic P. acnes strains which are sensitive or resis-
tant to erythromycin.5–7 This inhibition occurs at much lower
concentrations than with benzoyl peroxide. On P. acnes biofilm,
0.1% Myrtacine has two complementary actions: (i) very rapid
inhibitory action on biofilm formation, after 5 h of contact, and
(ii) destruction of biofilm, after 1 min of contact.6 Furthermore,
Myrtacine decreases the synthesis of proinflammatory media-
tors via the cyclooxygenase and lipooxygenase pathways, and the
lipase activity.5 This anti-inflammatory action of Myrtacine
was demonstrated by a sponsor-free, multicentre, prospective,
randomized, parallel-group study in 164 patients with mild to
moderate acne, who previously developed a retinoid dermatitis.8
One group of patients was treated with 0.2% Myrtacine and
4% nicotinamide (2 applications/day); the second group was
treated with a moisturizer (2 applications/day). Patients treated
with the Myrtacine/nicotinamide combination showed a sta-
tistically significant improvement in symptoms (pruritus, sting-
ing and burning sensation) as well as signs (erythema, dryness
and oedema).8 Good clinical results were observed also in
patients with nodular acne.9
The Myrtacine study published in this supplement to
JEADV demonstrates that (i) C. acnes colonization is high,
but not significantly different, in both patients with mild to
moderate acne and healthy control subjects, and (ii) phylotype
IA is predominant in acne patients. In addition, the authors
observed that a cream containing Myrtacine induced a
decrease in acne severity according to the Global Acne Severity
Scale (GEA), a decrease in non-inflammatory and inflamma-
tory lesions, reduced porphyrin synthesis by C. acnes and a
significantly reduced load of erythromycin-resistant strains of
C. acnes.4
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